Filtros de búsqueda

Lista de obras de Mario Tiribelli

"Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay." Is dPCR the key?

scientific article published on 07 July 2019

ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.

artículo científico publicado en 2017

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia

artículo científico publicado en 2017

ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome

artículo científico publicado en 2015

ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission

artículo científico publicado en 2016

Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma

artículo científico publicado en 2004

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells

artículo científico publicado en 2005

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

artículo científico publicado en 2015

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases

artículo científico publicado en 2003

BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.

artículo científico publicado en 2013

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

artículo científico publicado en 2017

Biological and clinical features of T-biphenotypic acute leukaemia: report from a single centre

scientific article published on 01 June 2004

Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy

artículo científico publicado en 2008

Cardiotoxicity of imatinib: At the heart of the problem

scientific article published on 01 January 2011

Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients

artículo científico publicado en 2007

Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.

artículo científico publicado en 2005

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera

scientific article published on 20 November 2014

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.

artículo científico publicado en 2015

Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.

artículo científico publicado en 2015

Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells

artículo científico publicado en 2007

Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse

artículo científico publicado en 2010

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

artículo científico publicado en 2017

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

artículo científico publicado en 2014

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

artículo científico publicado en 2018

Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70

article

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

artículo científico publicado en 2019

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

article

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations

artículo científico publicado en 2013

EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia

artículo científico publicado en 2013

Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells.

artículo científico publicado en 2005

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy

artículo científico publicado en 2019

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

scientific article published on 14 June 2019

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

artículo científico publicado en 2017

Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia

artículo científico publicado en 2002

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

artículo científico publicado en 2018

Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.

artículo científico publicado en 2006

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

artículo científico publicado en 2012

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

artículo científico publicado en 2018

FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience

artículo científico publicado en 2009

Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy

artículo científico publicado en 2014

Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients

artículo científico publicado en 2010

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

artículo científico publicado en 2008

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

artículo científico publicado en 2016

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

artículo científico publicado en 2006

Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology

artículo científico publicado en 2015

Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.

artículo científico publicado en 2013

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years

artículo científico publicado en 2008

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

artículo científico publicado en 2018

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

scientific article published on 02 September 2019

High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients

artículo científico publicado en 2017

Histone post-translational modifications associated to BAALC expression in leukemic cells

artículo científico publicado en 2011

How could patient reported outcomes improve patient management in chronic myeloid leukemia?

artículo científico publicado en 2016

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

artículo científico publicado en 2013

Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias

artículo científico publicado en 2004

Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis

scientific article published on 08 January 2007

Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response ⬇️

artículo científico publicado en 2015

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

scientific article published on 07 June 2019

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2012

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

scientific article published on 04 December 2018

Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.

artículo científico publicado en 2017

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

artículo científico publicado en 2008

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

artículo científico publicado en 2012

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

artículo científico publicado en 2018

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

artículo científico publicado en 2012

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

artículo científico publicado en 2019

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project

artículo científico publicado en 2018

Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia

artículo científico publicado en 2002

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

scientific article published on 01 February 2014

Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.

artículo científico publicado en 2015

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

artículo científico publicado en 2020

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment

artículo científico publicado en 2015

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib

artículo científico publicado en 2008

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia.

artículo científico publicado en 2002

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells

artículo científico publicado en 2011

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

artículo científico publicado en 2009

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

artículo científico publicado en 2012

Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.

artículo científico publicado en 2004

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy

artículo científico publicado en 2012

Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia

artículo científico publicado en 2008

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

scientific article published on 09 April 2020

Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients.

artículo científico publicado en 2009

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

artículo científico publicado en 2018

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia

artículo científico publicado en 2015

Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells

artículo científico publicado en 2006

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

artículo científico publicado en 2021

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

artículo científico publicado en 2018

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy

article

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

artículo científico publicado en 2020

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells

artículo científico publicado en 2007

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts

artículo científico publicado en 2007

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

artículo científico publicado en 2007

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia

artículo científico publicado en 2009

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2015

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells

artículo científico publicado en 2010

The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.

artículo científico publicado en 2007

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

scientific article published on 18 September 2019

The significance of early warning in chronic myeloid leukemia.

artículo científico publicado en 2017

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status

artículo científico publicado en 2012

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

scientific article published on 12 December 2019

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

artículo científico publicado en 2009

Two novel NPM1 mutations in a therapy-responder AML patient

artículo científico publicado en 2010

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data

artículo científico publicado en 2012

Unexpected phenotype of a typical NPM1 mutant.

artículo científico publicado en 2009

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

artículo científico publicado en 2007

What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda